BOULDER — Enliven Therapeutics Inc. (Nasdaq: ELVN), a Boulder-based oncology drug developer, has filed a shelf registration with the U.S. Securities and Exchange Commission to sell up to $200 million in shares.
A shelf registration allows a company to sell shares over a three-year period, if it decides to do so. Enliven’s shelf offering has not yet been declared effective by the SEC.
The company said it intends to use any proceeds from the offering to fund research and development, working capital and other purposes.
Enliven entered into an agreement with Jefferies LLC to operate as the company’s sales agent for any sale of the stock. Enliven also terminated an existing agreement with Cantor Fitzgerald & Co., which had operated as sales agent for a prior offering.Enliven in February completed its merger with Boston-based pharmaceutical company Imara Inc., concurrent with a $165 million raise.